Michael Yee
Stock Analyst at Jefferies
(3.53)
# 919
Out of 4,749 analysts
80
Total ratings
40.74%
Success rate
9.64%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRGX CARGO Therapeutics | Downgrades: Hold | $32 → $3 | $3.60 | -16.67% | 3 | Jan 30, 2025 | |
| ALXO ALX Oncology Holdings | Downgrades: Hold | $12 → $2 | $1.46 | +36.99% | 4 | Dec 19, 2024 | |
| KOD Kodiak Sciences | Upgrades: Buy | $20 | $6.40 | +212.50% | 3 | Dec 9, 2024 | |
| BIIB Biogen | Downgrades: Hold | $250 → $180 | $143.93 | +25.06% | 5 | Dec 9, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $500 → $550 | $461.68 | +19.13% | 4 | Dec 9, 2024 | |
| AMGN Amgen | Maintains: Buy | $380 | $285.42 | +33.14% | 5 | Nov 12, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $40 → $45 | $23.30 | +93.13% | 2 | Nov 1, 2024 | |
| MRNA Moderna | Maintains: Hold | $65 → $55 | $39.42 | +39.52% | 8 | Oct 15, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $35 | $10.01 | +249.65% | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $40 | $13.45 | +197.40% | 1 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $385 | $652.18 | -40.97% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1.4 → $10 | $2.31 | +332.90% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $1.94 | +54.64% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $30 | $25.92 | +15.74% | 2 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $3 → $1 | $0.58 | +73.49% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $20 | $40.38 | -50.47% | 3 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 → $75 | $25.80 | +190.70% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $2.01 | +1,392.54% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $32.88 | +97.69% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $45 | $0.48 | +9,203.29% | 2 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $1.79 | +1,575.98% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $14.23 | +110.82% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $14.01 | +756.53% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $70 → $75 | $25.08 | +199.10% | 2 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $13.58 | +120.91% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $11.01 | +599.36% | 2 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $97.20 | - | 3 | Jan 26, 2018 |
CARGO Therapeutics
Jan 30, 2025
Downgrades: Hold
Price Target: $32 → $3
Current: $3.60
Upside: -16.67%
ALX Oncology Holdings
Dec 19, 2024
Downgrades: Hold
Price Target: $12 → $2
Current: $1.46
Upside: +36.99%
Kodiak Sciences
Dec 9, 2024
Upgrades: Buy
Price Target: $20
Current: $6.40
Upside: +212.50%
Biogen
Dec 9, 2024
Downgrades: Hold
Price Target: $250 → $180
Current: $143.93
Upside: +25.06%
Vertex Pharmaceuticals
Dec 9, 2024
Upgrades: Buy
Price Target: $500 → $550
Current: $461.68
Upside: +19.13%
Amgen
Nov 12, 2024
Maintains: Buy
Price Target: $380
Current: $285.42
Upside: +33.14%
Denali Therapeutics
Nov 1, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $23.30
Upside: +93.13%
Moderna
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $39.42
Upside: +39.52%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $10.01
Upside: +249.65%
Oruka Therapeutics
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $13.45
Upside: +197.40%
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $652.18
Upside: -40.97%
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $2.31
Upside: +332.90%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $1.94
Upside: +54.64%
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $25.92
Upside: +15.74%
Oct 25, 2023
Downgrades: Hold
Price Target: $3 → $1
Current: $0.58
Upside: +73.49%
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $40.38
Upside: -50.47%
Jan 6, 2023
Upgrades: Buy
Price Target: $63 → $75
Current: $25.80
Upside: +190.70%
Nov 15, 2021
Initiates: Buy
Price Target: $30
Current: $2.01
Upside: +1,392.54%
Mar 2, 2021
Initiates: Buy
Price Target: $65
Current: $32.88
Upside: +97.69%
Mar 2, 2021
Downgrades: Hold
Price Target: $75 → $45
Current: $0.48
Upside: +9,203.29%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $1.79
Upside: +1,575.98%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $14.23
Upside: +110.82%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $14.01
Upside: +756.53%
Oct 12, 2020
Upgrades: Buy
Price Target: $70 → $75
Current: $25.08
Upside: +199.10%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $13.58
Upside: +120.91%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $11.01
Upside: +599.36%
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $97.20
Upside: -